Mankind pharma ipo

Mankind Pharma IPO: Three days bidding for the initial public offering (IPO) of Mankind Pharma Limited ended on Thursday and now focus has shifted on Mankind Pharma IPO allotment date, which is most likely on 3rd May 2023. As per Mankind Pharma IPO subscription status after closure of bidding, the public offer worth ₹4,326.36 crore has been subscribed 15.32 times. However, grey market has thumbs down the IPO despite positive trend in the secondary market for last four days. According to market experts, shares of Mankind Pharma Ltd is available at a premium of ₹60 in grey market today. Mankind Pharma IPO GMP today As per the market observers, Mankind Pharma IPO grey market premium (GMP) today is ₹60, which is ₹10 lower from its Thursday GMP of ₹70 per equity share. They said that dip in Mankind Pharma IPO GMP today can be attributed to the cold response being given by the retail investors to the public issue. They said that the IPO got stellar response in QIB category but in retail segment, the public issue failed to get fully subscribed. Hence, grey market, which is mainly driven by retail investors is giving cold response to the IPO. However, stock market experts maintained that GMP is not an ideal indicator about the success or failure of a public offer. One should stick to the basics and scan financials of the company as it gives concrete fundamental picture that is going to last for long. Mankind Pharma After three days of bidding, the public issue got subscribed 15.32...

Mankind Pharma Ltd. rallied 32% on its first day of trading in Mumbai after raising 43.3 billion rupees ($529 million) in one of India’s largest initial public offerings of the year. The drug and contraceptive maker’s stock jumped to as high as 1,430 rupees on Tuesday before closing at 1422.30 rupees. Its shareholders had sold 40 million shares at 1,080 rupees apiece at the IPO, the top of a marketed range that started from 1,026 rupees. Macquarie Research initiated coverage on the stock with an outperform rating.

Synopsis Indian pharma company Mankind Pharma is set to open its IPO next week. The offer for sale of 40 million equity shares by promoters and other existing shareholders is aiming to raise around INR4,326 crore ($523m). The price band has been set between INR1,026-1,080 per share, and subscriptions will be open to investors between 25 and 27 April with the shares likely to get listed on 9 May on both NSE and BSE The initial share sale of Mankind Pharma, probably the biggest so far this year, will open for subscription next week. The pharma company, known for its at-home pregnancy testing kits, announced the price band earlier this week. The IPO will be open on April 25 and close on April 27. The shares are likely to get listed on May 9 on both NSE and Here are 10 key things to know about the upcoming public offer 1) Issue Size and Structure The IPO is completely an offer for sale (OFS) of 40 million equity shares by promoters and other existing shareholders. Those selling shares in the OFS are promoters Ramesh Juneja, Rajeev Juneja, and Sheetal Arora. Besides, Cairnhill CIPEF, Cairnhill CGPE, Beige Limited, and Link Investment Trust will participate in the OFS. The offer size is worth about Rs 4,326 crore. 3) Company Overview Mankind Pharma is the fourth largest Indian pharmaceutical player in terms of domestic sales and third largest in sales volume for moving annual total as of December 2022. It has a pan-India marketing presence and operates 25 manufacturing facilitie...

The initial public offering of Mankind Pharma had been subscribed 15.32 times, largely on the back of qualified institutional buyers (QIBs), with bids coming in for 42.95 crore equity shares against an offer size 2.8 crore by noon on April 27, the final day of bidding. The issue size has been reduced to 2.8 crore shares from over 4 crore after the company mobilised Rs 1,298 crore through the anchor book on April 24. QIB investors had bid 49.16 times their allotted quota. The part set aside for high networth individuals was subscribed 3.80 times. The IPO has, so far, failed to enthuse retail investors who have only bid for 92 percent of the shares set aside for them. The pharmaceutical firm has reserved half of its issue size for QIBs, 15 percent for high-networth individuals and the remaining 35 percent for retail investors. The public issue, which is purely only an offer for sale, is aimed at fetching Mankind Pharma Rs 4,326.36 crore. The entire money, barring issue expenses, will go to selling shareholders, which are promoters as well as investors. The price band for the offer, which opened on April 25, is Rs 1,026-1,080 a share. Click Here To Read All IPO Related News Mankind Pharma is the biggest public issue of 2023, so far, in terms of size and the fifth of the year. Mankind Pharma, India's fourth-largest pharmaceutical company in terms of domestic sales and third-largest in terms of sales volume for MAT December 2022, manufactures a diverse range of pharmaceutical f...

Mankind Pharma Limited offers a IPO issue size of 40,058,844 equity shares worth of Rs 4326.36 Cr. Subscription of this IPO is opening from 25 Apr 2023 to 27 Apr 2023. The face value of the equity share is Rs 1 per share and the issue price band is ranging from Rs 1026 to Rs 1080 per share. and the minimum lot size is 13 shares and their multiples. Stay updated with us to know more about the Mankind Pharma Limited IPO Review including company overview, financial, live subscription, allotment, GMP, and more. Mankind Pharma IPO Details IPO Issue Opening Date: 25th Apr 2023 IPO Issue Closing Date: 27th Apr 2023 IPO Issue Price: ₹1026-1080 Per Share DRHP: Download DRHP RHP: Download RHP Anchor List: Download Anchor List IPO Listing At: BSE, NSE Retail Quota: Not less than 35% of the Net Issue IPO Issue Type: Book Build Issue IPO Issue Size: ₹4326.36 Cr Offer for Sale: ₹4326.36 Cr Face Value: ₹1 Per Equity Share IPO Discount: TBD Promoter Holding Pre IPO: 79.00% Promoter Holding Post IPO: 76.50% Allotment Status: Allotment Status BSE Code: 543904 NSE Code: MANKIND IPO Live GMP Mankind Pharma IPO Important Dates In this section we have covered all important dates related to Mankind Pharma IPO. Dates are updated as they are announced. The most noted dates are IPO start date and IPO end date, which one should use to participate in IPO. Mankind Pharma IPO important dates IPO Activity Date Basis of Allotment Date* 3rd May 2023 Refunds Initiation* 4th May 2023 Credit of Shares to Dem...

Review By Dilip Davda on Apr 19, 2023 •MPL is engaged in pharmaceutical products with a major focus on domestic markets. •It marked growth in its top and bottom lines from FY20 to FY22. •The company suffered a minor setback due to one-time adjustments of its recent takeovers. •Based on its recent financial performance the issue appears fully priced. •Investors may consider parking funds for the long term as this is a long racehorse. ABOUT COMPANY: Mankind Pharma Ltd. (MPL) is India's fourth largest pharmaceutical company in terms of Domestic Sales and third largest in terms of sales volume for MAT December 2022 (Source: IQVIA Dataset, IQVIA TSA MAT December 2022 Dataset for India (For FY20-22)). The company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. MPL is focused on the domestic market, as a result of which its revenue from operations in India contributed to 97.60% of total revenue from operations for the Financial Year 2022, which was one of the highest among peers identified by IQVIA (being key pharmaceutical companies operating in similar therapeutic areas, as highlighted in "Industry Overview" on page 158) ("Peers Identified by IQVIA") (Source: IQVIA Report). It operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at aff...

It was a strong debut for Mankind Pharma on May 9 as the counter zoomed 20 percent on the first tick itself before rallying a further 5 percent. Analysts believe you should not sell the stock as of now as the outlook is positive. Despite being an offer-for-sale by shareholders, the issue got a bumper subscription. Thus, before the listing, the market participants were expecting a strong start of its journey in the secondary market. “We recommend holding the stock for the long term as the company’s domestic sales are growing at 1.3 times the growth rate of the Indian pharmaceutical market,” said Astha Jain, Senior Research analyst at Hem Securities. “Mankind has several products in its portfolio within the top 10 rankings across key therapeutic areas along with established consumer healthcare franchises with brand recall. The company has a pan-India market and distribution coverage with focus on affordability and accessibility.” The company is almost entirely focussed on India. The domestic market contributed 97.60 percent to its revenue from operations in FY22, which recorded a 12 percent CAGR between FY18 and FY22 and 15 percent between FY20 and FY22, while the consumer healthcare products business accounted for 10 percent of domestic sales. Narendra Solanki, Head- Equity Research Anand Rathi Shares & Stock Brokers, pointed out that being one of the largest domestic pharma companies in India, Mankind is further strengthening its position in class 1 cities. This will b...

Mankind Pharma closed its maiden public issue on a strong note, getting subscribed over 15 times. Now all eyes will be on its share allotment which will be announced next week on May 3. The pharmaceutical company has received a robust response to its initial public offering from qualified institutional investors, who have bid 49.16 times the allotted quota, while high net-worth individuals have bought shares 3.8 times the reserved portion. However, the response from retail investors remained tepid, with only 92 percent of reserved shares subscribed. As a result, the offer has received bids for 42.95 crore equity shares subscribing 15.32 times during April 25-27. The company also received a good response in the anchor round with 16 MF schemes and names like CPPIB, Abu Dhabi Investment Authority, Goldman Sachs, Fidelity, Blackrock, GIS and Nomura participating. The Rs 4,326-crore public issue was entirely an offer for sale by promoters and investors. Hence all the money will go to the selling shareholders, and the company will not receive funds from this offer. The price band for the offer was Rs 1,026-1,080 per share and the final offer price is expected to be at the upper end of the price band. Investors in the Mankind Pharma IPO can check their share allotment status either on the BSE website or the portal of the IPO registrar, by following a few easy steps. In case of IPO registrar website, a) Select IPO "Mankind Pharma Limited" b) Select and accordingly enter either "Ap...

Mankind Mankind IPO GMP Today Mankind Pharma’s shares are currently trading at a premium of a whopping Rs 108 or 10 per cent up in the grey market, over the upper band of Rs 1,080 a share. So, the shares in the grey market are currently trading at Rs 1,188 apiece, on May 8. It indicates that the company’s shares are expected to be listed at a good premium over its issue price on May 8, 2023. The premium gets fluctuated based on the sentiments in the markets. On the company’s IPO price, analysts at brokerage firm Anand Rathi have said, “At the high (Rs 1,080) of the issue price band, the stock is valued at about 30x FY22 EPS of Rs 36. Pharma companies quote at an average P/E of 25x/22x FY24e/FY25e. We expect the company’s strong set of brands, focused approach to its chronic portfolio via recent acquisitions, launches and differentiated pipeline products to be key positives. However, risks are addition of NLEM lists, rise in raw material prices." Mankind Pharma IPO: Basic Details Mankind Pharma is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It has established several differentiated brands in condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparation categories. It has a pan-India marketing presence and operates 25 manufacturing facilities across the...

BENGALURU, May 9 (Reuters) - Shares of India's Mankind Pharma Ltd Mankind's 43.26 billion rupees initial public offering (IPO) ranks as India's biggest so far in 2023, and is also the largest among Indian pharma companies to go public since Gland Pharma Ltd Shares of the company, which also owns India's top at-home pregnancy test kit Prega News, opened at 1,300 rupees, well above its IPO price of 1,080 rupees, before surging 32.4% to a session-high of 1,430 rupees in heavy volumes. The company's successful debut comes amid a gloomy market for domestic listings. Since peaking in 2021 — when 183 firms went public, per data from Tracxn — the IPO market has fizzled out amid concerns of companies' valuations and profitability as well as the volatility in global markets. Reuters Graphics In the past six months, apparel retailer Even the companies that did go public in that period have not fared so well. For instance, KFin Technologies Ltd Mankind's debut could help revive the IPO market, said Hemang Jani, equity strategist at Motilal Oswal Financial Services. The company "clearly stands out as after a long time a company with good business model and performance numbers is listing. The strong debut will likely lift the sentiment for the IPO market overall." Its Manforce condoms is the top brand in the male condom category by sales in the Indian market, according to the company's IPO prospectus. It competes with Reckitt Benckiser Group's The company has become India's fourth-large...